NAMS Menopause Certification Exam Practice
Questions with correct Answers |Latest 2026/2027
INTRODUCTION
Prepare with confidence for the Menopause Society Certified Practitioner
(MSCP) exam using this premium, high-yield practice question bank
updated for the 2026/2027 testing cycle. Every clinical vignette is
meticulously drafted to match the core competency domains, including
STRAW+10 reproductive staging, hormone therapy algorithms, and
evidence-based non-hormonal management. This study resource serves
as an indispensable tool for nurse practitioners, certified midwives, and
physicians aiming to master advanced midlife women's health concepts
and pass their board certification on the first attempt.
Question 1
A 47-year-old woman presents with irregular menstrual periods. Her last
two cycles were 42 days and 21 days apart, respectively. She is
experiencing mild, intermittent hot flashes but is otherwise healthy.
According to the STRAW+10 (Stages of Reproductive Aging Workshop)
criteria, which stage best describes her current status?
A) Stage -3 (Late Reproductive)
B) Stage -2 (Early Menopausal Transition)
,C) Stage -1 (Late Menopausal Transition)
D) Stage +1a (Early Postmenopause)
Correct Answer: B) Stage -2 (Early Menopausal Transition)
Explanation: According to the STRAW+10 staging criteria, Stage
-2 (Early Menopausal Transition) is explicitly defined by a
variable cycle length with a persistent difference of 7 or more
days in consecutive cycles. Stage -1 (Late Menopausal
Transition) requires a clear history of skipped periods
resulting in an interval of amenorrhea lasting 60 days or more.
Because this patient exhibits high cycle variability without
prolonged skipped cycles of 60+ days, she rests squarely in
Stage -2.
Question 2
A 52-year-old postmenopausal woman with severe, disruptive vasomotor
symptoms (VMS) requests menopausal hormone therapy (MHT). She has a
history of well-controlled hypertension and a body mass index (BMI) of 34
kg/m². She has an intact uterus. Which of the following MHT regimens
carries the lowest relative risk for venous thromboembolism (VTE) while
adequately protecting her endometrium?
A) Oral conjugated equine estrogens (CEE) + oral medroxyprogesterone
acetate (MPA)
B) Oral micronized estradiol + oral micronized progesterone
,C) Transdermal estradiol patch + oral micronized progesterone
D) Transdermal estradiol patch alone
Correct Answer: C) Transdermal estradiol patch + oral
micronized progesterone
Explanation: Large observational studies and current
Menopause Society guidelines confirm that transdermal
estradiol avoids the hepatic first-pass effect, preventing the
up-regulation of clotting factors and thereby carrying little to
no increased risk of venous thromboembolism (VTE) compared
to oral estrogen options. Furthermore, because the patient has
an intact uterus, systemic estrogen must always be paired with
a progestogen to prevent endometrial hyperplasia or
carcinoma. Micronized progesterone is preferred over
synthetic progestins like MPA due to a more favorable
cardiovascular and breast profile.
Question 3
A 49-year-old patient who underwent a total hysterectomy with bilateral
salpingo-oophorectomy (BSO) for severe endometriosis 3 months ago
presents with intense hot flashes and night sweats. She has no personal
or family history of breast cancer or cardiovascular events. What is the
most appropriate first-line hormonal intervention for her symptoms?
A) Transdermal or oral estrogen-only therapy
, B) Combined estrogen-progestogen therapy
C) Low-dose oral contraceptives
D) Vaginal DHEA (Prasterone)
Correct Answer: A) Transdermal or oral estrogen-only therapy
Explanation: For a patient who has undergone a hysterectomy,
estrogen-only therapy (ET) is the standard of care to relieve
vasomotor symptoms. Progestogens are primarily indicated to
protect the endometrium from estrogen-induced hyperplasia;
therefore, they are unnecessary post-hysterectomy. While
some clinicians consider progestogens in patients with a
history of severe endometriosis to prevent the activation of
residual peritoneal implants, standard first-line therapy for
basic post-hysterectomy surgical menopause remains
estrogen alone. Low-dose oral contraceptives provide
supraphysiologic hormone levels and are inappropriate for a
postmenopausal profile.
Question 4
A 54-year-old woman presents with severe vaginal burning, dyspareunia,
and urinary urgency that began 2 years after her final menstrual period.
Physical exam shows pale, thin vaginal rugae and a vaginal pH of 6.0. She
has no history of hormone-dependent cancers. What is the recommended
first-line medical treatment for this condition?
Questions with correct Answers |Latest 2026/2027
INTRODUCTION
Prepare with confidence for the Menopause Society Certified Practitioner
(MSCP) exam using this premium, high-yield practice question bank
updated for the 2026/2027 testing cycle. Every clinical vignette is
meticulously drafted to match the core competency domains, including
STRAW+10 reproductive staging, hormone therapy algorithms, and
evidence-based non-hormonal management. This study resource serves
as an indispensable tool for nurse practitioners, certified midwives, and
physicians aiming to master advanced midlife women's health concepts
and pass their board certification on the first attempt.
Question 1
A 47-year-old woman presents with irregular menstrual periods. Her last
two cycles were 42 days and 21 days apart, respectively. She is
experiencing mild, intermittent hot flashes but is otherwise healthy.
According to the STRAW+10 (Stages of Reproductive Aging Workshop)
criteria, which stage best describes her current status?
A) Stage -3 (Late Reproductive)
B) Stage -2 (Early Menopausal Transition)
,C) Stage -1 (Late Menopausal Transition)
D) Stage +1a (Early Postmenopause)
Correct Answer: B) Stage -2 (Early Menopausal Transition)
Explanation: According to the STRAW+10 staging criteria, Stage
-2 (Early Menopausal Transition) is explicitly defined by a
variable cycle length with a persistent difference of 7 or more
days in consecutive cycles. Stage -1 (Late Menopausal
Transition) requires a clear history of skipped periods
resulting in an interval of amenorrhea lasting 60 days or more.
Because this patient exhibits high cycle variability without
prolonged skipped cycles of 60+ days, she rests squarely in
Stage -2.
Question 2
A 52-year-old postmenopausal woman with severe, disruptive vasomotor
symptoms (VMS) requests menopausal hormone therapy (MHT). She has a
history of well-controlled hypertension and a body mass index (BMI) of 34
kg/m². She has an intact uterus. Which of the following MHT regimens
carries the lowest relative risk for venous thromboembolism (VTE) while
adequately protecting her endometrium?
A) Oral conjugated equine estrogens (CEE) + oral medroxyprogesterone
acetate (MPA)
B) Oral micronized estradiol + oral micronized progesterone
,C) Transdermal estradiol patch + oral micronized progesterone
D) Transdermal estradiol patch alone
Correct Answer: C) Transdermal estradiol patch + oral
micronized progesterone
Explanation: Large observational studies and current
Menopause Society guidelines confirm that transdermal
estradiol avoids the hepatic first-pass effect, preventing the
up-regulation of clotting factors and thereby carrying little to
no increased risk of venous thromboembolism (VTE) compared
to oral estrogen options. Furthermore, because the patient has
an intact uterus, systemic estrogen must always be paired with
a progestogen to prevent endometrial hyperplasia or
carcinoma. Micronized progesterone is preferred over
synthetic progestins like MPA due to a more favorable
cardiovascular and breast profile.
Question 3
A 49-year-old patient who underwent a total hysterectomy with bilateral
salpingo-oophorectomy (BSO) for severe endometriosis 3 months ago
presents with intense hot flashes and night sweats. She has no personal
or family history of breast cancer or cardiovascular events. What is the
most appropriate first-line hormonal intervention for her symptoms?
A) Transdermal or oral estrogen-only therapy
, B) Combined estrogen-progestogen therapy
C) Low-dose oral contraceptives
D) Vaginal DHEA (Prasterone)
Correct Answer: A) Transdermal or oral estrogen-only therapy
Explanation: For a patient who has undergone a hysterectomy,
estrogen-only therapy (ET) is the standard of care to relieve
vasomotor symptoms. Progestogens are primarily indicated to
protect the endometrium from estrogen-induced hyperplasia;
therefore, they are unnecessary post-hysterectomy. While
some clinicians consider progestogens in patients with a
history of severe endometriosis to prevent the activation of
residual peritoneal implants, standard first-line therapy for
basic post-hysterectomy surgical menopause remains
estrogen alone. Low-dose oral contraceptives provide
supraphysiologic hormone levels and are inappropriate for a
postmenopausal profile.
Question 4
A 54-year-old woman presents with severe vaginal burning, dyspareunia,
and urinary urgency that began 2 years after her final menstrual period.
Physical exam shows pale, thin vaginal rugae and a vaginal pH of 6.0. She
has no history of hormone-dependent cancers. What is the recommended
first-line medical treatment for this condition?
